# C_2013035EN.01000501.xml

| 7.2.2013 | EN | Official Journal of the European Union | C 35/5 |
| --- | --- | --- | --- |

7.2.2013

EN

Official Journal of the European Union

C 35/5

---

Prior notification of a concentration

(Case COMP/M.6708 — BMS/Astrazeneca/Amylin Business)

Candidate case for simplified procedure

(Text with EEA relevance)

2013/C 35/06

| 1. | On 28 January 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Bristol-Myers Squibb Company (‘BMS’, USA) and AstraZeneca Pharmaceuticals LP (‘AZ’, UK) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Amylin Collaboration Business (‘Amylin Business’, USA) by way of acquisition of certain governance rights. |
| --- | --- |

1.

On 28 January 2013, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Bristol-Myers Squibb Company (‘BMS’, USA) and AstraZeneca Pharmaceuticals LP (‘AZ’, UK) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Amylin Collaboration Business (‘Amylin Business’, USA) by way of acquisition of certain governance rights.

1

| 2. | The business activities of the undertakings concerned are:






  — | AZ: primarily engaged in the discovery, development, manufacture and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious diseases, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

AZ: primarily engaged in the discovery, development, manufacture and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious diseases,

| — | BMS: active in the development and commercialization of treatments in several areas, in particular cardiovascular, virology (including HIV infection), oncology, neuroscience, immunoscience, and metabolics treatments, |
| --- | --- |

—

BMS: active in the development and commercialization of treatments in several areas, in particular cardiovascular, virology (including HIV infection), oncology, neuroscience, immunoscience, and metabolics treatments,

| — | Amylin Business: joint development and commercialization of four Amylin compounds, namely exenatide, pramlintide, metreleptin and AC165198. |
| --- | --- |

—

Amylin Business: joint development and commercialization of four Amylin compounds, namely exenatide, pramlintide, metreleptin and AC165198.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6708 — BMS/Astrazeneca/Amylin Business, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6708 — BMS/Astrazeneca/Amylin Business, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

(2)  OJ C 56, 5.3.2005, p. 32 (‘Notice on a simplified procedure’).

2

---